Jaime Rosenberg

Since the formation of the nonprofit generic drug company in January, the company has grown to 7 health systems and has named its chief operating officer. Orignally announced as Project Rx, the company will now be named Civica Rx.

Approximately 43% of patients using the Migraine Buddy app reported experiencing anxiety and/or depression during at least 1 migraine attack.

In addition to the advances made in the HIV space, such as antiretroviral therapies and pre-exposure prophylaxis, the years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.

In a 3-part series, the National Academy for State Health Policy explored how states can use policy levers to more effectively utilize limited resources and provide better care, improve care coordination services, and ensure consistent access to care for people living with HIV.

New study findings have identified a subtype of multiple sclerosis—myelocortical multiple sclerosis—that has neuronal loss but no demyelination of the brain’s white matter, indicating that demyelination and neuronal degeneration occur independently.

Newly published findings indicate that physician burnout is associated with an increased risk of patient safety incidents, poorer quality of care, and reduced patient satisfaction.

Targeted treatment interventions for populations with low levels of viral suppression, paired with tailored prevention packages, will be essential to ending the HIV epidemic in the United States, say researchers.

Building on prior research drawing a link between migraine and fibromyalgia comorbidity, a new study has found that fibromyalgia exacerbates depressive symptoms, migraine intensity, and migraine-related disability.

More than half of patients with multiple sclerosis (MS) in the BETASLEEP study indicated poor sleep quality, which was linked to fatigue and reduced quality of life over time.

Over 200 patient and provider groups have written to CMS, saying that proposed consolidation of evaluation and management billing codes will adversely affect the sickest Medicare patients and the physicians that treat them.

In 2016, the Next Generation Accountable Care Organization (ACO) model generated a net savings of $62 million to Medicare, representing a 1.1% net reduction in Medicare spending. In a webcast with the Accountable Care Learning Collaborative, CMS Administrator Seema Verma called the results a strong start and offered a look at what's in the future for the model.

Patients with HIV indicated a strong preference for “nice” over “rude” providers and a willingness to wait 19 hours more or travel 28 miles farther to see nice rather than rude providers.

A Health Affairs analysis showed a wide range of cost-effectiveness estimates for 30 of the most commonly prescribed cardiovascular drugs, suggesting that drug pricing is not consistently aligned with value.

Researchers found that pre-exposure prophylaxis (PrEP) usage is linked to routine care, such as influenza vaccination, tobacco and depression screening, and glucose testing.

The emergence and uptake of antiretroviral therapy (ART) has led to significant improvements in viral suppression rates over the past 2 decades.

Despite patients with migraine being younger and having fewer indicators for predicting readmission, they had an increased risk of 30-day hospital readmission due to pain.

Contrasting the excitement and optimism coming out of clinical research presented at the AIDS 2018 conference, there was a sobering takeaway in the political and advocacy sphere. Among the general consensus that we are in a fragile moment in time, there were several policies and advocacy efforts that made it to the forefront of the conference.

Patients using only in-network facilities still have at least 1 claim from an out-of-network provider in over 15% of inpatient admissions, according to an analysis from the Kaiser Family Foundation.

The 2018 International AIDS Conference in Amsterdam brought a plethora of new clinical implications for HIV care, reflecting ongoing investments in research efforts and optimism across all clinical domains, including vaccines, prevention, and new treatment approaches. However, with the excitement also came caution in other areas, such as stagnant incidence rates.

PatientPoint and Migraine Again have partnered to provide educational video content in nearly 5000 primary care and obstetrics/gynecology practices nationwide, offering patients and physicians insight into better managing migraine.

In a survey of 170 employers, employers indicated that they are taking a more activist role in delivering healthcare to their employees, expressed frustration with the pharmaceutical supply chain, and said they expect to see a large uptake of virtual healthcare in the coming years.

Just one-third of respondents of the Migraine in America 2018 survey, conducted by Health Union, are aware of calcitonin gene-related peptide (CGRP) inhibitors. Those who did know about the therapies had questions and concerns, such as cost, insurance coverage, and side effects.

A month after Symtuza's approval, Janssen announced new switch data on the treatment and a second study supporting its use in a rapid initiation scenario.

The FDA has approved several strengths of potassium chloride oral solutions as the first generic drugs to receive a Competitive Generic Therapy designation.

The lawsuit alleges that the pharmaceutical companies have conspired to fix, increase, stabilize, and/or maintain the price of a range of generic drugs, including antidepressants and beta-blockers.

Despite the presumption that larger practices that have more resources and are therefore better at providing care and improving outcomes, new research shows that they spend more on and have higher readmission rates for Medicare beneficiaries than smaller practices.

Instead of assessing a treatment’s impact solely on reductions in opioid use, the agency will take into account the effect of the treatment on things like emergency room admissions and infectious disease transmissions.

In 2017, generics accounted for 90% of prescriptions in the United States, and while brand name drugs accounted for just 10% of prescriptions, they were responsible for 77% of prescription spending.